HomeCompareGENE vs VICI

GENE vs VICI: Dividend Comparison 2026

GENE yields 261.44% · VICI yields 6.57%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GENE wins by $611.81M in total portfolio value
10 years
GENE
GENE
● Live price
261.44%
Share price
$0.77
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$612.80M
Annual income
$349,686,678.74
Full GENE calculator →
VICI
VICI Properties Inc.
● Live price
6.57%
Share price
$27.12
Annual div
$1.78
5Y div CAGR
44.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$988.8K
Annual income
$623,261.32
Full VICI calculator →

Portfolio growth — GENE vs VICI

📍 GENE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGENEVICI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GENE + VICI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GENE pays
VICI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GENE
Annual income on $10K today (after 15% tax)
$22,222.22/yr
After 10yr DRIP, annual income (after tax)
$297,233,676.93/yr
VICI
Annual income on $10K today (after 15% tax)
$558.67/yr
After 10yr DRIP, annual income (after tax)
$529,772.12/yr
At 15% tax rate, GENE beats the other by $296,703,904.81/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GENE + VICI for your $10,000?

GENE: 50%VICI: 50%
100% VICI50/50100% GENE
Portfolio after 10yr
$306.90M
Annual income
$175,154,970.03/yr
Blended yield
57.07%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on VICI right now

GENE
No analyst data
Altman Z
-24.5
Piotroski
2/9
VICI
Analyst Ratings
20
Buy
6
Hold
Consensus: Buy
Price Target
$31.60
+16.5% upside vs current
Range: $30.00 — $33.00
Altman Z
1.4
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GENE buys
0
VICI buys
0
No recent congressional trades found for GENE or VICI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGENEVICI
Forward yield261.44%6.57%
Annual dividend / share$2.00$1.78
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%44.3%
Portfolio after 10y$612.80M$988.8K
Annual income after 10y$349,686,678.74$623,261.32
Total dividends collected$585.16M$948.4K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: GENE vs VICI ($10,000, DRIP)

YearGENE PortfolioGENE Income/yrVICI PortfolioVICI Income/yrGap
1← crossover$36,844$26,143.79$11,368$948.43+$25.5KGENE
2$129,445$90,022.09$13,339$1,493.16+$116.1KGENE
3$434,094$295,587.53$16,326$2,426.21+$417.8KGENE
4$1,390,885$926,404.44$21,123$4,112.15+$1.37MGENE
5$4,262,362$2,774,115.59$29,379$7,368.23+$4.23MGENE
6$12,505,839$7,945,111.88$44,804$14,191.64+$12.46MGENE
7$35,167,310$21,786,062.26$76,658$29,972.12+$35.09MGENE
8$94,885,057$57,256,035.19$150,894$71,015.81+$94.73MGENE
9$245,903,396$144,376,384.91$350,814$193,582.47+$245.55MGENE
10$612,803,313$349,686,678.74$988,809$623,261.32+$611.81MGENE

GENE vs VICI: Complete Analysis 2026

GENEStock

Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include cardiovascular, type 2 diabetes, prostate cancer, and melanoma. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

Full GENE Calculator →

VICIREIT

VICI Properties is an experiential real estate investment trust that owns one of the largest portfolios of market-leading gaming, hospitality and entertainment destinations, including the world-renowned Caesars Palace. VICI Properties' national, geographically diverse portfolio consists of 29 gaming facilities comprising over 48 million square feet and features approximately 19,200 hotel rooms and more than 200 restaurants, bars and nightclubs. Its properties are leased to industry leading gaming and hospitality operators, including Caesars Entertainment, Inc., Century Casinos Inc., Hard Rock International, JACK Entertainment and Penn National Gaming, Inc. VICI Properties also owns four championship golf courses and 34 acres of undeveloped land adjacent to the Las Vegas Strip. VICI Properties' strategy is to create the nation's highest quality and most productive experiential real estate portfolio.

Full VICI Calculator →
📬

Get this GENE vs VICI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GENE vs SCHDGENE vs JEPIGENE vs OGENE vs KOGENE vs MAINGENE vs NNNGENE vs EPRTGENE vs ADC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.